Reishi Fatigue Randomized Trial: What the Evidence Says

Quick Answer

Reishi Fatigue Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Studies have suggested that CFS may be associated with an abnormal immune response, possibly due to a viral infection. [Sarvestan Javad (2026); evidence level 2]
• Patients with CFS/ME may have higher levels of inflammatory markers, such as cytokines, or evidence of impaired immune function, such as decreased natural killer cell activity. [Sarvestan Javad (2026); evidence level 2]
• It also critically evaluates the current level of evidence and highlights key limitations related to standardization, variability of extracts, and clinical applicability. [Sadowska Anna (2026); evidence level 3]
• Notably, a fungus calledwas found among the belongings of the world's oldest human mummy, estimated to be about 4000 years old. [Sadowska Anna (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For reishi fatigue randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Sarvestan Javad (2026). Effectiveness and Safety of a Supplement Containing a Pharmacologically Active Basidiomycete Mushroom for Chronic Fatigue and Post–COVID-19 Fatigue Syndrome: Protocol for a Randomized Controlled Trial. DOI: 10.2196/82633. PMCID: PMC12869150. PMID: 41558017. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12869150/
• Sadowska Anna (2026). Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential. DOI: 10.3390/molecules31101749. PMCID: PMC13209540. PMID: 42197308. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13209540/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.